Lumryz

Active Ingredient(s): Sodium Oxybate
FDA Approved: * May 1, 2023
Pharm Company: * AVADEL CNS
Category: Narcolepsy
* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Lumryz 4.5 g/1 Oral for Suspension, Extended Release
NDC: 13551-001
Labeler:
Avadel Cns Pharmaceuticals, LLC
Lumryz 6 g/1 Oral for Suspension, Extended Release
NDC: 13551-002
Labeler:
Avadel Cns Pharmaceuticals, LLC
Lumryz 7.5 g/1 Oral for Suspension, Extended Release
NDC: 13551-003
Labeler:
Avadel Cns Pharmaceuticals, LLC
Lumryz 9 g/1 Oral for Suspension, Extended Release
NDC: 13551-004
Labeler:
Avadel Cns Pharmaceuticals, LLC

Related Brands

Drugs with the same active ingredients